painful diabetic peripheral neuropathy. Diabetic polyneuropathy
Conditions
Interventions
Intervention 1: The gabapentin group receives the gabapentin at a dose of 300 mg per day. Then, the dose of 300 mg increases every three days to reach 900 mg per day (300 mg three times per day) and t
Sponsors
Vice chancellor for research of Ahvaz Jundishapur University of Medical Sciences Department of Neuro
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: aged>18 rule out other DDx. for peripheral neuropathy do nt use drug for treatment of DPNP duration of diabetes ranging from 1 to 15 years HbA1C less than 10 mg A pain score of at least 40 mm on the 100 mm visual analogue scale (VAS)
Exclusion criteria
Exclusion criteria: patients who were already on other medication for the treatment of DPNP one week prior to the study enrolment hepatic failure; ;renal failure with GFR<30 ml/min concurernt of psycologic disoeder cardiac arhythmia patients with established neuropathy due to other causes;, history of epilepsy drug abuse uncontoroled acute close angle Glocoma recent MI patients who did not give written informed consent pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Before treatment and 1,4 and 8 weeks after treatment. Method of measurement: visual analogue scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep quality. Timepoint: Before treatment and 1,4 and 8 weeks after treatment. Method of measurement: Sleep interference score.;Changes in clinical status. Timepoint: 1,4and 8 weeks after treatment. Method of measurement: Clinical Global Impression of Change. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHosein Kaveiani
Ahvaz University of Medical Sciences
Outcome results
None listed